期刊文献+

炔基苯氧乙酸类CRTH2拮抗剂的3D-QSAR研究 被引量:1

3D-QSAR studies on Alkynyl phenoxy acetic acids as potent CRTH2 inhibitors
下载PDF
导出
摘要 目的建立CRTH2拮抗剂的3D-QSAR模型。方法采用比较力场分析(CoMFA)法和比较分子相似性指数分析(CoMSIA)法对103个炔基苯氧乙酸类CRTH2拮抗剂进行三维定量构效关系(3D-QSAR)研究,建立了具有良好预测能力的模型。结果 CoMFA法所建模型的交互验证系数q2为0.763,线性回归系数r2为0.931,最佳主成分数是6。CoMSIA法采用立体场、静电场、疏水场、氢键供体场所建模型性能最佳,其中q2和r2分别为0.644、0.904;最佳主成分数是6。结论 3D-QSAR模型及力场贡献值分析揭示了分子结构和结合常数间的关系,为今后的炔基苯氧乙酸类化合物的设计改造提供了更直接可行的线索。 CRTH2 receptor plays an important role in the nosogenesis of inflammatory diseases. In this study, the 3D-QSAR of 103 alkynyl acetic acid antagonists was analyzed by CoMFA and CoMSIA methods to establish a good predictive model. The best 3D-QSAR model was obtained with cross-validated correlation coefficient q^2 values, the calibrated correlation coefficient (r^2) and principal-component (n) of 0.763, 0.931 and 6 for CoMFA, respectively. The best results of CoMSIA model was built by steric, electrostatic, hydrophobic, hydrogen bond aeceptor field. The q^2 values, r^ and n of CoMSIA are 0.644, 0.904 and 6. The result reveals the relationship between molecular structure and binding constant, and would benefits the future rational design of potent antagonists.
出处 《免疫学杂志》 CAS CSCD 北大核心 2014年第6期539-544,549,共7页 Immunological Journal
基金 重庆市自然科学基金重点项目(CSTC 2013 JJB10004) 国家自然科学基金项目(81171508 31170747) 重庆市教委科技项目(KJ130809) 重庆巴南区科技计划专项(2012Q119)
关键词 炔基苯氧乙酸 酶结合常数 三维定量关系研究 哮喘 Alkynylphenoxyacetic acid Inhibitory constant 3D-QSAR Asthma
  • 相关文献

参考文献21

  • 1Matsuoka T, Hirata M, Tanaka H, et al. Prostaglandin D2 as a mediator of allergic asthma[J]. Science, 2000, 287(5460): 2013-2017.
  • 2Kostenis E, Ulven T. Emerging roles of DP anti CRTH2 in allergic inflammation[J]. Trends Mol Med, 2006, 12(4): 148-158.
  • 3Hansen G, Berry G, DeKruyff RH, et al. Allergen-specific Th1 cells fail to counterbalance Th2 cell - induced airway hyperreactivity but cause severe airway inflammation[J]. J Clin Invest, 1999, 103(2): 175-183.
  • 4Luster AD, Tager AM. T-cell trafficking in asthma: lipid mediators grease the way[J]. Nat Rev Immunol, 2004, 4(9): 711-724.
  • 5Gervais FG, Cruz RP, Chateauneuf A, et al. Selective modulation of chemokinesis, degranulation, and apoptosis in eosinophils through the PGD2 receptors CRTH2 and DP[J]. J Allergy Clin Immunol, 2001, 108(6): 982-988.
  • 6Gibbs B. Human basophils effeetors and immunomodulators of allergic inflammation and innate immunity[J]. Clin Exp Med, 2005, 5(2): 43-49.
  • 7Nagata K, Hirai H. The second PGD2 receptor CRTH2: structure, properties, and functions in leukocytes [J]. Prostaglandins Leukot Essent Fatty Acids, 2003, 69(2): 169-177.
  • 8Pettipher R, Hansel TT, Armer R. Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases[J]. Nat Rev Drug Discov, 2007, 6(4): 313-325.
  • 9阎昱升,汤渝玲.支气管哮喘患者血清IL-25、ECP、IL-27的测定及临床意义[J].免疫学杂志,2013,29(10):912-914. 被引量:9
  • 10Tilley SL, Coffman TM, Koller BH. Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes[J]. J Clin Invest, 2001, 108(1): 15-23.

二级参考文献33

  • 1张旭华,周丽,张锦,冯俭,李银环,张生山.哮喘患者气道阻塞的可逆性分析[J].宁夏医学院学报,2004,26(6):426-427. 被引量:2
  • 2Thorley lawson DA, Gross A. Persistence of the epstein- Barr virus and the origins of associated lymphomas [J]. N Engl J Med, 2004, 350(13): 1328-1337.
  • 3Young LS, Rickinson AB. Epstein-Barr virus: 40 years on[J]. Nat Rev Cancer, 2004, 4(10): 757-768.
  • 4Zhong Y. Epstein-barr vires infection and lymphoproliferative disorder after hematopoietic cell transplantation[J]. Clin J Oncol Nurs, 2012, 16(2): 211-214.
  • 5Martorelli D, Muraro E, Merlo A, et al. Exploiting the interplay between innate and adaptive immunity to improve immunotherapeutic strategies for epstein-Barr-virus-driven disorders[J]. Clin Dev Immunol, 2012,2012: 931952.
  • 6Palucka K, Ueno H, Banchereau J. Recent developments in cancer vaccines[J]. J Immunol, 2011, 186(3): 1325-1331.
  • 7Madan RA, Gulley JL. The current and emerging role of immunotherapy in prostate cancer[J]. Clin Genitourin Cancer, 2010, 8(1): 10-16.
  • 8Lafuente EM, Reche P. Prediction of MHC-peptide binding: a systematic and comprehensive overview [J]. Curr Pharm Des, 2009, 15(28): 3209-3220.
  • 9Roomp K, Antes I, Lengauer T. Predicting MHC class I epitopes in large datasets[J]. BMC Bioinformatics, 2010, 11: 90-100.
  • 10E1 Manzalawy Y, Dobbs D, Honavar V. On evaluating MHC-II binding peptide prediction methods[J]. PLoS One, 2008, 3(9): e3268.

共引文献9

同被引文献13

  • 1Saha A, Kaul R, Kmurakami M, et al. Tumor viruses and cancer biology: modulating signaling pathways for therapeutic intervention[J]. Cancer Biol Ther, 2010, 10(10): 961-978.
  • 2Munz C, Moormann A. Immune escape by Epstein-Barr virus associated malignancies[J]. Semin Cancer Biol, 2008, 18(6): 381-378.
  • 3Herbst H, Stein H, Niedobitek G. et al. Epstein-Barr virus and CD30 malignant lymphomas[J]. Crit Rev Oncog, 1993,4(2): 191.
  • 4Tanner J, Weis J, Fearon D, et al. Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis [J]. Cell,1987, 50(2): 203-213.
  • 5Coffey A J, Brooksbank RA, Brandau O, et al. Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene[J]. Nat Genet, 1998, 20(2): 129-135.
  • 6KUppers R. B cell under influence:transformation of B cell by Epstein-barr virus[J]. Nat Rev Immunol, 2003, 3(10): 801-812.
  • 7Pender MP. The essential role of Epstein-Barr virus in the pathogenesis of multiple sclerosis[J]. Neuroscientist, 2011, 17(4): 351-367.
  • 8Draborg Draborg AH, Duus K, Houen G. Epstein-Barr virus and systemic lupus erythromatosus[J]. Clin Dev lmmunol, 2012, 2012: 3750516.
  • 9Frahm N, Korber BT, Adams CM, et al. Consistent cytotoxie-T-lymphocyte targeting of immuno-dominant regions in human immunodeflciency virus across multiple ethnicities[J]. J Virol, 2004, 78(5): 2187-2200.
  • 10Lossius A, Johansen JN, Torkildsen O, et al. Epstein-Barr virus in systemic lupus erythromatosus, rheumatoid arthritis and multiple sclerosis-association and causation [J]. Viruses, 2012, 4(12): 3701-3730.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部